Gastroenterology

Syncrosome and the Microbiome … Follow us at Pharmabiotics2018

Syncrosome invites you to visit us at Pharmabiotics2018, March 14th to November 15th 2018, in Paris, France. This Conference dedicated to the Microbiome will keep Syncrosome's team up to date in this new area of development!Emmanuelle Bettendorf, our Business Developer would be delighted to meet you...

A new therapeutic target to treat chronic inflammatory disease

Ulcerative Colitis is a chronic and relapsing inflammatory disease. Inflammation plays a major part in the symptoms of this disease that is characterized by pro-inflammatory cytokine production, leukocyte infiltration, and consequent structural and functional damage to the gut. There is still a lot that remains...

Evaluating preclinical emesis induced and nausea by PDE4 inhibitors

Emesis and/or Nausea are commonly reported side effects associated with several drugs such as 4 phosphodiesterase (PDE4) inhibitors and is a major drawback for the therapeutic use of these drugs. The mechanism responsible for this side effect has been investigated in an attempt to discover...

Syncrosome at the next Microbiome & Probotics Forum in Amsterdam

The 4th Microbiome R&D and Business collaboration Forum will feature 2 days of interactive presentations, poster presentation and networking opportunity, in Amsterdam (Netherlands) from 3 to 4th of April. This conference will offer a complete programme focusing on preclinical animal model and specific focuses :Probiotics and Digestive Health (Roles...